semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Sickle Cell Disease FOR WITH CELL IN PAIN 1. Age 18 years or older. 2. Diagnosis of sickle cell anemia: 1. Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required). 2. Acute onset pain crisis in a distribution typical for that subject, onset within the last 7 days and for which hospitalization and parenteral narcotic pain treatment are required. 3. Ability to provide informed written consent  FOR WITH CELL IN PAIN 1. Pregnancy. 2. History of non-trivial injury, burns, surgery or skin ulcers on the arms. 3. Carrier of drug resistant bacteria that normally requires isolation while visiting a hospital. 4. Administration of any of the following drugs within the last 14 days Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil) Endothelin-1 receptor blockers (bosentan, sitaxentan, ambrisentan, tezosentan) Nitric oxide donors (nitroglycerin, nitroprusside, nitrates) 5. Ingestion of caffeine within the 12 hours before the start of the study appointment, or tobacco use within the 30 days before the study appointment. 6. Diagnosis with any of the following chronic diseases or conditions Uncontrolled high blood pressure (systolic blood pressure must not be greater than 160 mmHg or diastolic blood pressure greater than 90 mmHg) Uncontrolled high cholesterol (total cholesterol must not be greater than 240 mg/dL) Uncontrolled diabetes (must not have both a documented history of diabetes and random blood glucose of greater than 200 mg/dL) Chronic kidney disease (serum creatinine must not be greater than 2 mg/dL) Coronary artery disease Peripheral vascular disease 7. Received a blood transfusion within 7 days of the study procedure. CELL IN STATE FOR WITH CELL IN STATE: 1. Age 18 years or older. 2. Diagnosis of sickle cell anemia: a.Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required). 3. Ability to provide informed written consent
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 20.0-79.0,  Chronic Kidney Disease Type 2 Diabetes CKD patients with type 2 diabetes mellitus Patients whose eGFR levels are eligible for this study Patients being treated with stable dose of ACE inhibitors and/or ARB etc  Patients with Type 1 diabetes Patients with known non-diabetic renal disease Patients with a history of renal transplantation Patients with mean SBP > 160 mmHg or mean DBP > 90 mmHg Patients with HbA1C > 10% Patients with cardiovascular disease specified in the study protocol etc
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acute Pancreatitis clinical diagnosis of severe acute pancreatitis written informed consent Time from onset of abdominal pain to admission ≤ 72 hours SIRS score ≥ 2  confirmed infection pregnancy patients needing emergency operation for abdominal compartment syndrome chronic renal diseases needing blood purification previous exploratory laparotomy for acute abdomen and diagnosis of pancreatitis during laparotomy acute flare-up of chronic pancreatitis malignancy
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 10.0-12.0,  Child Healthy and physically active (as determined by medical and activity questionnaire) 12 years of age Within approximately 2 years of estimated age of peak height velocity (PHV) Minimum aerobic fitness of 35 ml/kg/min as assessed by the McMaster All-out Progressive Continuous Cycling Protocol Having obtained his/her informed assent Having obtained his/her legal representative's informed consent  Post-pubertal Taking any medication Smoker Undergoing medical treatment or investigations Body mass index > 24 Suffer from chronic diseases (with regular intake of drugs, medical history) Vegetarians Vaccination in the last 4 months Any know food allergies or intolerance Pregnancy
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Diabetic Polyneuropathy Diabetic Gastroparesis Diabetes Mellitus age > 50 years written informed consent Diabetes mellitus (only Diabetes mellitus group) Symptoms of diabetic gastroparesis with respect to nausea, postprandial fullness, abdominal pain, nausea, vomiting, abdominal bloating, early satiety, erratic blood glucose levels and weight loss evaluated by a standardized questionnaire (only Diabetes mellitus group) actually measured HbA1c (only Diabetes mellitus group)  Subject who is pregnant or breast feeding Subject unwilling or unable to comply with study requirements Any investigational agent or participation in another clinical trial within 28 days prior to randomization Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results Known allergy to the investigational product, to any of its excipients Active inflammatory bowel disease, serious gastric ulceration or other bowel diseases like e.g. coeliac disease Implanted cardiac cardioverter-defibrillator or cardiac pacemaker Stenosis or stricture of gastrointestinal tract or any surgery in this region except for cholecystectomy or appendectomy Long-term medication with drug, that influence gastrointestinal motility (opiate, opioids, erythromycin, metoclopramide, laxatives) < 3 days before randomisation and before magnetic marker monitoring
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Pancreatitis All adult patients >18y.o Diagnosis of acute pancreatitis (defined as an amylase >3 times the upper limit of normal and typical symptoms)  Inability to provide informed consent Declines participation Uretheral catheterisation not required on clinical grounds
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Effect of NOAC on POCT The indication for the use of NOAC is provided by the attending physician. The for and  for the use of the new oral anticoagulants must meet appropriate and the clinical guidelines that are described in the SOPs. Patients treated with dabigatran 2x150mg / d for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation are included. Moreover, patients treated with rivaroxaban 20 mg / d for DVT prophylaxis and treatment of recurrent DVT or PE are included
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 45.0-75.0,  Diabetes Type 2 The diagnosis of type 2 diabetes will be based on the WHO guidelines. These are 2 fasting plasma glucose readings of greater than 7.0mmoll-1 or 2 random plasma glucose readings >11mmoll-1 in the absence of symptoms or concurrent illness or medication which might lead to hyperglycaemia (e.g. thiazide diuretics). Or one reading meeting the diagnostic level with the presence of symptoms of polyuria, polydipsia, nocturia, fatigue or blurring of vision. The final diagnostic method of diagnosis type 2 diabetes is a positive oral glucose tolerance test (OGTT) using a 75g glucose load. If doubt exists on the diagnosis of diabetes an OGTT will be performed Diabetes managed by diet alone or diet and metformin. If metformin is used the dose should have been stable for a minimum of 3 months prior to the start of the study Hba1c up to and including 9.9% Age 45-75 If female, should be post-menopausal BMI 25-39kgm-2 Patients will have attended a structured group patient education programme (and be on stable medication for hypertension, lipids and gout (if appropriate) for 3 months prior to entry into the study. Subjects will be encouraged to incorporate the chocolate into their diet as advised during the education programme Having obtained his/her or his/her legal representative's informed consent  Patients with concurrent illness or any changes in medication in the last 3 months Patients whose diabetes is managed with TZDs, DPP-IV inhibitors, GLP-1 analogues, insulin or sulphonylureas or prandial regulators Patients not wishing to allow disclosure to their GPs Pregnancy Hba1c at recruiting stage of >10.0% Patient who cannot be expected to comply with treatment Currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study Patients who consuming more than 20g/d of chocolate or having a very high polyphenol content of their diet, who are not willing to change their diet Patients taking high dose antioxidant supplements including single and multivitamin preparations including A,C,E Women on HRT treatment
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Bacterial Infection Due to Helicobacter Pylori (H. Pylori) Male or female subject ages 3 to 1711/12 years. 2. Subject with upper gastrointestinal signs and symptoms (e.g., abdominal pain/discomfort, bloating, nausea, or vomiting, etc.) 3. Subject and/or parent/legal guardian is capable of giving assent or consent. 4. Subject is able to complete the urea breath test by investigator's assessment  Subject is hypersensitive to mannitol, citric acid and/or aspartame. 2. Previous diagnosis of phenylketonuria (PKU. 3. Subject with difficulty swallowing or who may be at high risk for aspiration due to medical or physical conditions. 4. Subjects with ongoing respiratory conditions or on bronchodilators that may compromise the collection of breath samples. 5. Subjects with severe chronic illness (e.g., Crohn's disease, leukemia, kidney diseases, etc.) 6. Administration of bismuth preparations (e.g., Pepto-Bismol®) at anytime within 14 days prior to the testing. 7. Administration of antibiotics (e.g., amoxicillin, tetracycline, metronidazole, clarithromycin, azithromycin, etc.) therapy at anytime within 14 days prior to the testing. 8. Administration of proton pump inhibitors (PPI; e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, pantoprazole, etc.) at anytime within 14 days prior to the testing. 9. Administration of Histamine H2 receptor antagonist (H2RA; e.g., ranitidine, cimetidine, famotidine, nizatidine, etc.) at anytime within 24 hours prior to the testing. 10. Treatment for eradication of H pylori within 28 days before testing or retesting. 11. Participation in a drug or device study within 30 days of testing
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metabolic Syndrome Hypercholesterolemia Hypertriglyceridemia Hyperglycemia waist circumference of ≥ 94 cm (males) or ≥ 80 cm (females) plus any two of the following blood pressure ≥ 130/85 or taking antihypertensive medication fasting plasma glucose (FPG) > 100 mg/dL serum triglycerides (TG) > 150 mg/dL high-density lipoprotein (HDL) < 40 mg/dL in men,and < 50 mg/dL in women-  using insulin or glucose sensitizing medication preexisting cardiovascular disease psychiatric problems non-compliance of patients not presenting at times determined for treatment and evaluation
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Eosinophilic Esophagitis Food Allergies Male and female subjects 18 years and older 2. Previous diagnosis of eosinophilic esophagitis with clinical symptoms including heartburn, dysphagia, vomiting, epigastric pain, recurrent vomiting, food impaction as well > 15 eosinophils per high powered field (400x magnification) by endoscopic esophageal biopsy in both the proximal and distal esophagus 3. Previous diagnosis of gastroesophageal reflux with < 15 eosinophils per high powered field (400x magnification) by endoscopic biopsy  Male and female subjects less than 18 years of age 2. Pregnant female subjects 3. Subjects who are receiving systemic steroids and are unable to stop prior to enrollment 4. Subjects who are receiving systemic antihistamines and are unable to stop prior to enrollment 5. Subjects who are unable to cooperate/comply with study procedures or communicate with investigator in order to successfully complete the study 6. Subjects with severe skin disorders such as atopic dermatitis, dermatographism, or psoriasis who would be unable to complete skin or patch testing 7. Subjects with an infirmity, disability, or geographical location which seems likely to prevent regular attendance for patient visit -
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 20.0-74.0,  Diabetes, Type 2 Patients who completed Study 262-09-001 (namely, patients who visited the hospital at visit Week 24） Patients who are capable of giving informed consent prior to participating in this clinical study Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after the study (end of the post-observation period)  Patients who withdrew from Study 262-09-001 Patients who experienced serious adverse events that the relationship with the study drug was not denied in Study 262-09-001 Patients who experienced serious adverse events that the relationship with the study drug are denied in Study 262-09-001 and whose symptoms are still emerged at the time of initiation of this study Patients who met the of Study 262-09-001 during the study period of Study 262-09-001 Female patients who wish to become pregnant during the study period of Study 262-09-002 or within 4 weeks after the study Patients otherwise judged by the investigator or subinvestigator to be inappropriate for in the study